Median Progression-Free Survival (PFS)
Rd Continuous (n=535) 25.5 mo (95% CI 20.7, 29.4)
Rd18
(n=541) 20.7 mo (95% CI 19.4, 22.0)
MPT
(n=547) 21.2 mo (95% CI 19.3, 23.2)
100
Survival Probability (%)
80
Rd Continuous vs MPT
Rd Continuous vs Rd18
Rd18 vs MPT
60
HR (95% CI)
Logrank P value (2-sided)
0.72 (0.61, 0.85) P<0.0001
0.70 (0.60, 0.82)
1.03 (0.89, 1.20)
Planned duration of
treatment in the Rd18
40 and MPT arms was
18 months
20
0
0
1
2
3
4
5
Progression-Free Survival (Years)
•535
PFS
Rd Continuous
Rd18
541
MPT MM-020
547
Study design: The
Events:
(52.0%),
(64.3%), MPT=334/547
400Rd Continuous=278/535
319
265
218 Rd18=348/541
168
105
55
19 (61.1%)2
391
380
(FIRST)
319
265
167
304
244
compared
REVLIMID170+
108
116
low-dose
56
30
58
28 (Rd)
dexamethasone
7
2
6
1
Continuous
until
0
0
0
progression,
trial
fixed-cycle
MPT, and fixed-cycle Rd18. MM-020 was a Phase 3, randomized, multicenter, open-label, 3-arm study enrolling 1623 newly diagnosed
Number
of Subjects
at mg
Risk
patients who did not receive a stem cell transplant (SCT).
REVLIMID
was given 25
once daily orally on Days 1 to 21 of 28-day cycles,
PFS Events:
Rd Continuous=278/535
(64.3%),
(61.1%) ≤75 years and 20 mg for patients
and dex was dosed once
daily orally
on Days 1, 8, 15,(52.0%),
and 22Rd18=348/541
of each 28-day
cycleMPT=334/547
(40 mg for patients
>75 years). The primary endpoint in the trial was progression-free survival (PFS), as the time from randomization to the first documentation
of disease progression as determined by Independent Response Adjudication Committee (IRAC), based on International Myeloma Working
Group (IMWG) criteria, or death due to a